<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31474" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Zolmitriptan</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abram</surname>
            <given-names>Jasmine A.</given-names>
          </name>
          <aff>Florida International University Herbert Wertheim College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Priti</given-names>
          </name>
          <aff>Un of Florida College of Pharmacy</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jasmine Abram declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Priti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31474.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Zolmitriptan is a pharmaceutical medication utilized for managing and treating acute migraines. Zolmitriptan belongs to the triptan class of drugs that targets migraine symptoms and provides relief to patients.&#x000a0;The underlying cause of migraines can be attributed to localized cranial vasodilatation coupled with the discharge of neuropeptides, including calcitonin gene-related peptide, vasoactive intestinal peptide (VIP), and substance P, within the trigeminal system.&#x000a0;Zolmitriptan is&#x000a0;a selective 5-hydroxytryptamine (5-HT) 1B/1D receptor agonist with moderate affinity for the 5-HT 1A receptor subtypes. Zolmitriptan's interaction with 5-HT 1B/1D receptors induces vasoconstriction of intracranial blood vessels, concurrently inhibiting the release of proinflammatory neuropeptides from trigeminal perivascular nerve endings. This educational activity provides insights into the applications, mechanism of action, and contraindications of zolmitriptan as a valuable agent in treating acute migraines. This activity also highlights the&#x000a0;adverse events, toxicity concerns, and other pivotal considerations, including off-label applications, dosage guidelines, pharmacokinetics, monitoring procedures, and relevant interactions, which are crucial for healthcare practitioners when managing migraine issues and associated ailments in patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Screen patients for contraindications, potential drug interactions, and underlying health conditions that could influence zolmitriptan's safe and effective use.</p></list-item><list-item><p>Implement zolmitriptan into treatment plans, considering factors such as dosage, formulation, timing of treatment, and administration routes based on individual patient needs.</p></list-item><list-item><p>Apply evidence-based guidelines to optimize the use of zolmitriptan for migraine management, including proper patient education on medication administration, potential adverse effects, and early treatment initiation.</p></list-item><list-item><p>Communicate effectively with patients about zolmitriptan therapy's benefits, risks, and potential adverse effects, ensuring they are informed and engaged in shared decision-making with their healthcare providers.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31474&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31474">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31474.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The U.S. Food and Drug Administration (FDA) has&#x000a0;approved the use of zolmitriptan in specific indications, ensuring its safe and regulated application in medical practice.&#x000a0;Zolmitriptan is available in oral and nasal spray formulations for the acute management of migraines across various patient populations and presentations.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral zolmitriptan&#x000a0;is indicated for acute migraines in adults, both with and without aura, offering a versatile approach to managing different migraine presentations.<xref ref-type="bibr" rid="article-31474.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nasal spray zolmitriptan is indicated&#x000a0;for the acute treatment of migraines in adults and&#x000a0;pediatric patients aged 12 and older, providing a comprehensive solution for migraine management across various age groups.<xref ref-type="bibr" rid="article-31474.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Zolmitriptan has been found to have off-label uses for the following purposes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute treatment of cluster headaches when administered as a nasal spray, as endorsed by a Level A recommendation from the American Academy of Neurology (AAN).<xref ref-type="bibr" rid="article-31474.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Managing menstrual migraines.<xref ref-type="bibr" rid="article-31474.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute migraine headaches and related symptoms include nausea, vomiting, phonophobia, and photophobia.<xref ref-type="bibr" rid="article-31474.r1">[1]</xref><xref ref-type="bibr" rid="article-31474.r4">[4]</xref><bold>&#x000a0;</bold></p>
          </list-item>
        </list>
        <p>Zolmitriptan showed significant efficacy in helping patients attain pain-free status at 2 hours, 3 hours, and 4 hours following the treatment, compared to the placebo group.<xref ref-type="bibr" rid="article-31474.r5">[5]</xref><xref ref-type="bibr" rid="article-31474.r6">[6]</xref><xref ref-type="bibr" rid="article-31474.r7">[7]</xref>&#x000a0;</p>
        <p>In a multicenter, randomized, placebo-controlled trial, administering 5 mg zolmitriptan nasal spray to patients resulted in a notable 2-hour headache response rate of 70.3%, demonstrating a significant increase compared to the placebo group.<xref ref-type="bibr" rid="article-31474.r4">[4]</xref></p>
      </sec>
      <sec id="article-31474.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The underlying cause of migraines can be attributed to localized cranial vasodilatation coupled with the discharge of neuropeptides, including calcitonin gene-related peptide, vasoactive intestinal peptide (VIP), and substance P, within the trigeminal system.&#x000a0;Zolmitriptan is&#x000a0;a selective 5-hydroxytryptamine (5-HT) 1B/1D receptor agonist with moderate affinity for the 5-HT 1A receptor subtypes.<xref ref-type="bibr" rid="article-31474.r8">[8]</xref></p>
        <p>Zolmitriptan's interaction with 5-HT 1B/1D receptors induces vasoconstriction of intracranial blood vessels, concurrently inhibiting the release of proinflammatory neuropeptides from trigeminal perivascular nerve endings.<xref ref-type="bibr" rid="article-31474.r9">[9]</xref> The presence of radioactive [3H]-zolmitriptan within the cells of the trigeminal nucleus caudalis and nucleus tractus solitarius has demonstrated zolmitriptan's ability to penetrate the blood-brain barrier.<xref ref-type="bibr" rid="article-31474.r10">[10]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption: Zolmitriptan is rapidly absorbed in the bloodstream&#x000a0;following its oral administration through tablets and orally disintegrating tablet (ODT) forms. Zolmitriptan exhibits linear kinetics across the dosage spectrum ranging from 2.5 to 50 mg. Food does not significantly influence the bioavailability of zolmitriptan. Zolmitriptan has a rapid onset of action and is detected in the brain within 5 minutes of intranasal administration.<xref ref-type="bibr" rid="article-31474.r11">[11]</xref>&#x000a0;</p>
        <p>Zolmitriptan nasal spray undergoes rapid absorption through the nasopharynx, a phenomenon elucidated by a positron emission tomography (PET) study using 11C-labeled zolmitriptan. The nasal spray formulation displays a mean comparative bioavailability of 102%, in contrast to the oral tablet's bioavailability of 40%.</p>
        <p>Distribution: Zolmitriptan exhibits a plasma protein binding of 25%. The mean apparent volume of distribution (Vd) measures 7 L/kg.<xref ref-type="bibr" rid="article-31474.r12">[12]</xref><xref ref-type="bibr" rid="article-31474.r13">[13]</xref></p>
        <p>Metabolism: Zolmitriptan undergoes hepatic metabolism, primarily mediated by the cytochrome P450 enzyme CYP1A2, forming 3 major metabolites. Approximately two-thirds of the parent compound metabolizes into the active derivative <italic toggle="yes">N</italic>-desmethyl-zolmitriptan (183C91). Simultaneously, the remaining one-third&#x000a0;of zolmitriptan transforms into 2 inactive metabolites: zolmitriptan&#x000a0;<italic toggle="yes">N</italic>-oxide and an indole acetic acid derivative. Owing&#x000a0;to the metabolite's heightened 5HT1B/1D potency, which surpasses that of zolmitriptan by 2 to 6 times, <italic toggle="yes">N</italic>-desmethyl-zolmitriptan significantly contributes to the overall therapeutic effect following zolmitriptan administration.</p>
        <p>The pharmacokinetics of the <italic toggle="yes">N</italic>-desmethyl metabolite are similar to that of zolmitriptan for all nasal spray doses. The <italic toggle="yes">N</italic>-desmethyl metabolite becomes detectable in the plasma within 15 minutes, with its peak plasma concentration (Tmax) typically reached around 3 hours following administration. A recent study revealed that CYP2D6 is the primary enzyme responsible for the metabolic activation of zolmitriptan. This process involves the conversion of zolmitriptan into an &#x003b1;,&#x003b2;-unsaturated imine intermediate by the action of CYP2D6.<xref ref-type="bibr" rid="article-31474.r14">[14]</xref></p>
        <p>Elimination: Zolmitriptan has an elimination half-life of approximately&#x000a0;3 hours. The primary route of elimination for the drug is renal excretion, with its clearance exceeding the glomerular filtration rate, suggesting the involvement of renal tubular secretion in the excretion process.<xref ref-type="bibr" rid="article-31474.r15">[15]</xref><xref ref-type="bibr" rid="article-31474.r16">[16]</xref></p>
      </sec>
      <sec id="article-31474.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Zolmitriptan is available in various formulations, including oral tablets, ODTs, and nasal spray, each available in 2.5 mg or 5 mg strengths. The recommended maximum daily dosage of zolmitriptan for adults is 10 mg.<xref ref-type="bibr" rid="article-31474.r17">[17]</xref><bold>&#x000a0;</bold></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The&#x000a0;recommended adult dosages of zolmitriptan in its various available formulations are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral tablet: Zolmitriptan's clinical effectiveness remains unaffected whether administered with food and water or on an empty stomach.<xref ref-type="bibr" rid="article-31474.r12">[12]</xref> This attribute benefits individuals experiencing unpredictable migraines that can manifest anytime, day or night.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>ODT: Patients should receive guidance to maintain the tablet within its blister packaging until they intend to consume it. The suggested approach involves placing the ODT on the patient's tongue for dissolution and subsequent swallowing of the medication along with saliva.&#x000a0;The initial recommended dosage for zolmitriptan is either 1.25 mg or 2.5 mg. In cases necessitating the lower 1.25 mg dosage, the functionally scored 2.5 mg tablet can be split manually. The maximum recommended dose of zolmitriptan ODT for a single administration is 5 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nasal spray: Zolmitriptan nasal spray is typically initiated with a recommended starting dose of 2.5 mg and a maximum single dose of 5 mg. If necessary, a second dose of zolmitriptan&#x000a0;can be administered after 2 hours, with the caveat that the cumulative dose should not surpass 10 mg within 24 hours.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p>Hepatic impairment:&#x000a0;Diminished metabolic activity results in a prolonged half-life and elevated plasma concentrations of zolmitriptan, potentially leading to intensified peripheral vasoconstrictive effects, including high blood pressure.<xref ref-type="bibr" rid="article-31474.r18">[18]</xref>&#x000a0;Hepatic enzymes play a pivotal role in the metabolism of zolmitriptan, underscoring the necessity for individuals with severe hepatic impairment to reduce their daily intake. This adjustment is imperative as severe hepatic impairment has been shown to modify zolmitriptan's pharmacokinetics, notably resulting in decreased metabolism.<xref ref-type="bibr" rid="article-31474.r12">[12]</xref>&#x000a0;</p>
        <p>As the manufacturer's labeling outlines, zolmitriptan blood concentrations can escalate in moderate-to-severe hepatic impairment cases.&#x000a0;Notably, a subset of these patients exhibited a significant rise in blood pressure. Therefore, a prudent approach involves dosage reduction of zolmitriptan and exercising caution when prescribing the drug for individuals with moderate-to-severe hepatic impairment.</p>
        <p>Renal impairment:&#x000a0;As per the manufacturer's guidelines, zolmitriptan clearance diminishes by 25% in individuals with severe renal impairment, whereas no substantial alteration in clearance was noted in cases of moderate renal impairment. In scenarios involving severe renal impairment, thoughtful consideration of dosage adjustment is advised.</p>
        <p>Pregnancy considerations:&#x000a0;The manufacturer's labeling indicates no data concerning the developmental risk associated with using zolmitriptan during pregnancy. Furthermore, in reproductive studies conducted on rats and rabbits, administering zolmitriptan orally to pregnant animals led to fetal malformations occurring at clinically relevant exposures. As a result, it is advisable to consider alternative medications for migraine management during pregnancy.</p>
        <p>Breastfeeding considerations:&#x000a0;Preliminary evidence indicates that zolmitriptan is present in breast milk at a low concentration. The amount of zolmitriptan consumed by the breastfeeding infant is minimal and is not expected to have a significant impact, especially when the infant is older than 2 months. The prescriber should be aware that if prophylactic propranolol is used simultaneously, the breastfeeding infant may receive a significantly enhanced dose of zolmitriptan.<xref ref-type="bibr" rid="article-31474.r19">[19]</xref></p>
        <p>Pediatric patients: Zolmitriptan is approved by the FDA for treating acute migraines in individuals aged 12 or&#x000a0;older. Nasal spray formulations of zolmitriptan offer a more convenient administration option for adolescents grappling with migraines associated with nausea and vomiting. As the AAN and American Headache Society (AHS) guidelines outline, clinicians can prescribe 5 mg of zolmitriptan nasal spray to pediatric patients.<xref ref-type="bibr" rid="article-31474.r6">[6]</xref></p>
        <p>Older&#x000a0;patients: For older patients, it is advisable to initiate zolmitriptan at lower doses, taking into account potential declines in hepatic, renal, or cardiac function. Before starting zolmitriptan therapy, older patients with risk factors should undergo a comprehensive cardiovascular assessment.</p>
      </sec>
      <sec id="article-31474.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Dysgeusia is the most commonly observed adverse effect of zolmitriptan in healthy individuals, with the nasal spray causing a more significant impact. This phenomenon is likely attributed to the method of drug administration through the nasal route. Additional minor adverse events reported with intranasal zolmitriptan usage include nasal passage irritation, dizziness, throat irritation, and fatigue. Furthermore, phase 1 trials of the Real Life Intranasal Zolmitriptan Exposure (REALIZE) study revealed that the encountered adverse effects did not result in participants discontinuing the medication.<xref ref-type="bibr" rid="article-31474.r20">[20]</xref><bold>&#x000a0;</bold></p>
        <p>The Treatment of Acute Migraine Headache in Adolescents (TEENZ) constituted a double-blind, randomized controlled trial with over 700 pediatric participants. The outcomes of this trial provide additional support to the adverse event patterns observed in the REALIZE trial, where dysgeusia remained the most prevalent adverse event.<xref ref-type="bibr" rid="article-31474.r5">[5]</xref></p>
        <p>Cardiovascular adverse drug reactions associated with&#x000a0;zolmitriptan include increased systolic blood pressure in older adults, while increased diastolic blood pressure was noted in both older and younger patients. Moreover, a dose-dependent increase in sedation has also been observed in patients taking zolmitriptan.<xref ref-type="bibr" rid="article-31474.r15">[15]</xref></p>
        <p>A&#x000a0;risk of&#x000a0;headaches exists in individuals resulting from either medication withdrawal or drug overuse.<xref ref-type="bibr" rid="article-31474.r3">[3]</xref></p>
        <p>Zolmitriptan exhibits a low affinity for 5-HT 1A receptors, which carries implications for the potential development of serotonin syndrome. The amalgamation of autonomic and neuromuscular symptoms that constitute the serotonin syndrome can emerge due to the activation of both central and peripheral 5-HT receptors, mainly the 5-HT 1A and 5-HT 2A receptor subtypes.<xref ref-type="bibr" rid="article-31474.r8">[8]</xref></p>
        <p>Other adverse effects or risks associated with&#x000a0;zolmitriptan usage in patients are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Risks associated with phenylketonuria: The ODTs of zolmitriptan&#x000a0;contain phenylalanine, a constituent of aspartame, which can be detrimental for individuals with phenylketonuria. However, according to&#x000a0;the manufacturer's labeling, zolmitriptan tablets do not contain phenylalanine.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Postmarketing case report: A noteworthy incident involved a woman who, over a year, progressively escalated her zolmitriptan usage and subsequently experienced transient myopia alongside heightened intraocular pressures.<xref ref-type="bibr" rid="article-31474.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hepatotoxicity: Isolated cases of cholestatic hepatitis following zolmitriptan usage have been documented. Typically, these injury instances manifested within 1 to 2 weeks of consuming multiple doses of zolmitriptan during an extended and intense migraine episode.<xref ref-type="bibr" rid="article-31474.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal infarction: This condition has been reported with the use of zolmitriptan.<xref ref-type="bibr" rid="article-31474.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dose-response&#x02013;based network meta-analysis:&#x000a0;The utilization of zolmitriptan at 10 mg was linked to a greater relative risk of paresthesia.<xref ref-type="bibr" rid="article-31474.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Cimetidine, a CYP1A2 inhibitor, elevates zolmitriptan and 183C91 levels within the systemic circulation. Consequently, this accentuates the exposure to the vasoconstrictive effects of the drug, necessitating a reduction in the total daily zolmitriptan dosage for individuals using such inhibitors.<xref ref-type="bibr" rid="article-31474.r16">[16]</xref></p>
        <p>Zolmitriptan exhibited no substantial interactions with acetaminophen or metoclopramide, which are commonly incorporated into regimens for addressing headache symptoms.<xref ref-type="bibr" rid="article-31474.r25">[25]</xref></p>
        <p>The use of oral contraceptives among female study participants did not significantly impact the medication's efficacy or tolerability.<xref ref-type="bibr" rid="article-31474.r12">[12]</xref></p>
      </sec>
      <sec id="article-31474.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Understanding the contraindications associated with zolmitriptan is crucial for ensuring safe and effective management of acute migraines and other conditions. The contraindications associated with&#x000a0;zolmitriptan use are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Individuals with a known hypersensitivity to zolmitriptan or&#x000a0;at risk of angioedema or anaphylaxis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals with cerebrovascular or cardiovascular disease due to the presence of 5-HT 1B receptors in coronary arteries. These conditions encompass myocardial infarction, Prinzmetal angina, stroke, transient ischemic attack, and peripheral vascular disease.<xref ref-type="bibr" rid="article-31474.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals with a history of coronary artery disease, including myocardial infarction, Prinzmetal angina, and angina pectoris.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals with Wolff-Parkinson-White (WPW) syndrome or those with arrhythmias linked to other cardiac accessory conduction pathway disorders.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals with ischemic bowel disease or uncontrolled hypertension.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals with hemiplegic or basilar migraine due to their heightened risk of stroke.<xref ref-type="bibr" rid="article-31474.r26">[26]</xref><xref ref-type="bibr" rid="article-31474.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals who concurrently use other triptans or medications containing ergotamine within 24 hours.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals who concurrently&#x000a0;use or have recently discontinued monoamine oxidase (MAO-A) inhibitors within 2 weeks.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31474.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Physicians recommend administering the initial dose of zolmitriptan in a medically supervised environment and subsequently conducting an electrocardiogram for patients with multiple cardiovascular risk factors.&#x000a0;Regular cardiovascular assessments are advised for high-risk patients on long-term zolmitriptan treatment. Clinicians should consistently monitor blood pressure in all zolmitriptan patients due to the medication's vasoconstrictive effects, with heightened attention directed toward individuals with hepatic impairment. Noteworthy indicators of elevated blood pressure include headaches and palpitations.<xref ref-type="bibr" rid="article-31474.r18">[18]</xref></p>
      </sec>
      <sec id="article-31474.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In pediatric cases, zolmitriptan toxicity did not result in life-threatening complications; however, the common signs of toxicity included tachycardia, dyspnea, and vomiting.<xref ref-type="bibr" rid="article-31474.r27">[27]</xref> Zolmitriptan overdoses have been linked to hypertension, tachycardia, and drowsiness in adults.<xref ref-type="bibr" rid="article-31474.r28">[28]</xref> Furthermore, there have been 2 documented cases of hepatotoxicity associated with zolmitriptan use.<xref ref-type="bibr" rid="article-31474.r29">[29]</xref>&#x000a0;</p>
        <p>Although the potential for medication overuse headaches exists, this risk can be mitigated through patient education on correct medication administration practices.<xref ref-type="bibr" rid="article-31474.r3">[3]</xref>&#x000a0;Currently, no specific antidote for zolmitriptan is available. In cases of severe drug overdose, it is recommended to establish and uphold a clear airway, ensure proper breathing, and maintain circulation.</p>
      </sec>
      <sec id="article-31474.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Headaches, including migraines, constitute a prevalent neurological concern. Therefore, collaborating with patients&#x000a0;enhances the competence of&#x000a0;healthcare providers to gain a clearer understanding of their headache experiences and develop an&#x000a0;effective treatment plan. Triptans exhibit their most remarkable efficacy when administered at the onset of the headache phase rather than the prodromal phase. Patients educated about their medication use reported heightened comprehension of the optimal conditions for managing their headaches and recognizing contraindications.<xref ref-type="bibr" rid="article-31474.r30">[30]</xref></p>
        <p>Furthermore, healthcare providers must also consider patients' medication affordability, considering different health insurers' variations in medication coverage. Commercial and government health insurers tend to offer coverage for generic triptans, whereas commercial insurers more commonly cover brand triptans. This insurance coverage dynamic is essential for both healthcare providers and patients. Insurance plans can impose limitations on the type of formulation and may mandate the fulfillment of step therapy criteria&#x000a0;before extending coverage for specific formulations.<xref ref-type="bibr" rid="article-31474.r31">[31]</xref></p>
        <p>
<bold>Recommendations</bold>
</p>
        <p>In 2006, the FDA issued an alert concerning serotonin syndrome linked to the concurrent usage of triptan drugs with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). However, skepticism remains regarding the actual prevalence of this adverse event.<xref ref-type="bibr" rid="article-31474.r32">[32]</xref> To exemplify, <italic toggle="yes">JAMA Neurology</italic> published a secondary data analysis utilizing electronic health record data to assess outcomes of patients who were prescribed triptans alongside SSRIs or SNRIs. Among the 19,017 patients in the study, 17 were considered suspected cases, while 2 met the diagnostic criteria for definite cases.<xref ref-type="bibr" rid="article-31474.r32">[32]</xref></p>
        <p>Furthermore, an evaluation of the 29 cases upon which the FDA alert was founded revealed that only 7 cases satisfied Sternbach criteria, while none met the Hunter criteria. Although the precipitation of serotonin syndrome appears rare, the healthcare team must remain vigilant about its potential occurrence due to the gravity of the condition.<xref ref-type="bibr" rid="article-31474.r33">[33]</xref></p>
        <p>The AHS and the AAN provide evidence-based guidelines on headache treatment that healthcare providers can use to guide their decisions on&#x000a0;zolmitriptan treatment. Although the FDA may not currently approve zolmitriptan for treating cluster headaches, the AAN has issued a Level A recommendation endorsing the utilization of both oral and intranasal zolmitriptan for managing acute cluster headaches.</p>
        <p>The management of headaches in patients undergoing zolmitriptan therapy often involves the participation of interprofessional healthcare providers. Hence, establishing a close collaboration, maintaining open communication, and engaging in shared decision-making among&#x000a0;clinicians, pharmacists, and other medical professionals is essential to ensure effective patient care. Adopting an interprofessional team approach enhances efficacy, reduces the incidence of adverse drug reactions associated with zolmitriptan therapy, and ultimately improves patient outcomes.</p>
      </sec>
      <sec id="article-31474.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31474&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31474">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31474/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31474">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31474.s11">
        <title>References</title>
        <ref id="article-31474.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKeage</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older.</article-title>
            <source>Paediatr Drugs</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-81</page-range>
            <pub-id pub-id-type="pmid">26747634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maasumi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kriegler</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Menstrual Migraine and Treatment Options: Review.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>194</fpage>
            <page-range>194-208</page-range>
            <pub-id pub-id-type="pmid">27910087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinclair</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sturrock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Matharu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Headache management: pharmacological approaches.</article-title>
            <source>Pract Neurol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>411</fpage>
            <page-range>411-23</page-range>
            <pub-id pub-id-type="pmid">26141299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charlesworth</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Dowson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Purdy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Boes-Hansen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>F&#x000e4;rkkil&#x000e4;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.</article-title>
            <source>CNS Drugs</source>
            <year>2003</year>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>653</fpage>
            <page-range>653-67</page-range>
            <pub-id pub-id-type="pmid">12828501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Farkas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>&#x00160;tillov&#x000e1;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Woodruff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liss</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lillieborg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raines</surname>
                <given-names>S</given-names>
              </name>
              <collab>TEENZ Study Group</collab>
            </person-group>
            <article-title>Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ).</article-title>
            <source>Headache</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>1107</fpage>
            <page-range>1107-19</page-range>
            <pub-id pub-id-type="pmid">27329280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oskoui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Holler-Managan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Potrebic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Billinghurst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hershey</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Licking</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sowell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Victorio</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gersz</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Leininger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zanitsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yonker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Sep</month>
            <day>10</day>
            <volume>93</volume>
            <issue>11</issue>
            <fpage>487</fpage>
            <page-range>487-499</page-range>
            <pub-id pub-id-type="pmid">31413171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Network meta-analysis of migraine disorder treatment by NSAIDs and triptans.</article-title>
            <source>J Headache Pain</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <pub-id pub-id-type="pmid">27957624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scotton</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions.</article-title>
            <source>Int J Tryptophan Res</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>1178646919873925</fpage>
            <pub-id pub-id-type="pmid">31523132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yates</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>S&#x000f6;rensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bergstr&#x000f6;m</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Antoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nairn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>L&#x000e5;ngstr&#x000f6;m</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dane</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Distribution of intranasal C-zolmitriptan assessed by positron emission tomography.</article-title>
            <source>Cephalalgia</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>12</issue>
            <fpage>1103</fpage>
            <page-range>1103-9</page-range>
            <pub-id pub-id-type="pmid">16305598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.</article-title>
            <source>Cephalalgia</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>17 Suppl 18</volume>
            <fpage>4</fpage>
            <page-range>4-14</page-range>
            <pub-id pub-id-type="pmid">9399012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yates</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nairn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Dane</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>42</volume>
            <issue>11</issue>
            <fpage>1244</fpage>
            <page-range>1244-50</page-range>
            <pub-id pub-id-type="pmid">12412823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dixon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Warrander</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The clinical pharmacokinetics of zolmitriptan.</article-title>
            <source>Cephalalgia</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>17 Suppl 18</volume>
            <fpage>15</fpage>
            <page-range>15-20</page-range>
            <pub-id pub-id-type="pmid">9399013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koteswari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sravanthi</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Mounika</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohammed Rafi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Nirosha</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Formulation development and evaluation of zolmitriptan oral soluble films using 2<sup>2</sup> factorial designs.</article-title>
            <source>Int J Pharm Investig</source>
            <year>2016</year>
            <season>Oct-Dec</season>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>201</fpage>
            <page-range>201-206</page-range>
            <pub-id pub-id-type="pmid">28123989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Metabolic activation of zolmitriptan mediated by CYP2D6.</article-title>
            <source>Xenobiotica</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>51</volume>
            <issue>11</issue>
            <fpage>1292</fpage>
            <page-range>1292-1302</page-range>
            <pub-id pub-id-type="pmid">34096834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Seaber</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Layton</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Weatherley</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Rolan</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>342</fpage>
            <page-range>342-53</page-range>
            <pub-id pub-id-type="pmid">9542478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dixon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sellers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yates</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome p450 on its pharmacokinetics in healthy volunteers.</article-title>
            <source>Clin Drug Investig</source>
            <year>1998</year>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>515</fpage>
            <page-range>515-22</page-range>
            <pub-id pub-id-type="pmid">18370509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bigal</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sheftell</surname>
                <given-names>FD</given-names>
              </name>
            </person-group>
            <article-title>The triptan formulations : how to match patients and products.</article-title>
            <source>CNS Drugs</source>
            <year>2003</year>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>431</fpage>
            <page-range>431-47</page-range>
            <pub-id pub-id-type="pmid">12697002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dixon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sellers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leclerc</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Delvaux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rautureau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effect of hepatic impairment on the pharmacokinetics of zolmitriptan.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>694</fpage>
            <page-range>694-701</page-range>
            <pub-id pub-id-type="pmid">9725544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Zolmitriptan</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>5</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30000523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gawel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aschoff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Charlesworth</surname>
                <given-names>BR</given-names>
              </name>
              <collab>REALIZE Study Team</collab>
            </person-group>
            <article-title>Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.</article-title>
            <source>Headache</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-16</page-range>
            <pub-id pub-id-type="pmid">15663607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JTL</given-names>
              </name>
              <name>
                <surname>Skalicky</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced Myopia and Bilateral Angle Closure Secondary to Zolmitriptan.</article-title>
            <source>J Glaucoma</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>10</issue>
            <fpage>954</fpage>
            <page-range>954-956</page-range>
            <pub-id pub-id-type="pmid">28858962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Serotonin Receptor Agonists (Triptans)</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>2</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31644023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fulton</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Renal infarction during the use of rizatriptan and zolmitriptan: two case reports.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2006</year>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-80</page-range>
            <pub-id pub-id-type="pmid">16615676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasan Abdi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sayed</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Bhaskar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Serotonin Receptor agonist and Risk of Paresthesia in Migraine Patients: A Dose-Response Model-Based (Network) Meta-Analysis.</article-title>
            <source>Ann Indian Acad Neurol</source>
            <year>2022</year>
            <season>Jul-Aug</season>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>669</fpage>
            <page-range>669-675</page-range>
            <pub-id pub-id-type="pmid">36211148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seaber</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Ridout</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Layton</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peck</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1997</year>
            <volume>53</volume>
            <issue>3-4</issue>
            <fpage>229</fpage>
            <page-range>229-34</page-range>
            <pub-id pub-id-type="pmid">9476036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Acute Migraine Treatment in Adults.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>778</fpage>
            <page-range>778-93</page-range>
            <pub-id pub-id-type="pmid">25877672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larivi&#x000e8;re</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Garat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nisse</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mathieu-Nolf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Pediatric poisoning with triptans: review of cases in the Lille poison center between 2000 and 2010].</article-title>
            <source>Arch Pediatr</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>254</fpage>
            <page-range>254-9</page-range>
            <pub-id pub-id-type="pmid">22306360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robblee</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Butterfield</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Triptan and ergotamine overdoses in the United States: Analysis of the National Poison Data System.</article-title>
            <source>Neurology</source>
            <year>2020</year>
            <month>Apr</month>
            <day>07</day>
            <volume>94</volume>
            <issue>14</issue>
            <fpage>e1460</fpage>
            <page-range>e1460-e1469</page-range>
            <pub-id pub-id-type="pmid">31792093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fernandez-Atutxa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vergara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miquel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanchez-Delgado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Rizatriptan-induced liver toxicity. Report of a case].</article-title>
            <source>Gastroenterol Hepatol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>261</fpage>
            <page-range>261-3</page-range>
            <pub-id pub-id-type="pmid">23084593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baron</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lettich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hastriter</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lovell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kalidas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
              <collab>American Headache Society Headache Fellows Research Consortium</collab>
            </person-group>
            <article-title>Triptan education and improving knowledge for optimal migraine treatment: an observational study.</article-title>
            <source>Headache</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>686</fpage>
            <page-range>686-97</page-range>
            <pub-id pub-id-type="pmid">24520930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minen</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Lindberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Langford</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loder</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>57</volume>
            <issue>8</issue>
            <fpage>1243</fpage>
            <page-range>1243-1251</page-range>
            <pub-id pub-id-type="pmid">28691382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orlova</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rizzoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Loder</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome.</article-title>
            <source>JAMA Neurol</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>566</fpage>
            <page-range>566-572</page-range>
            <pub-id pub-id-type="pmid">29482205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31474.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports.</article-title>
            <source>MedGenMed</source>
            <year>2007</year>
            <month>Sep</month>
            <day>05</day>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>48</fpage>
            <pub-id pub-id-type="pmid">18092054</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
